-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Combination therapy with trastuzumab and fulvestrant is a treatment option for patients with hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer; however, this combination therapy is currently being evaluated Efficacy studies are still limited
.
Therefore, there are retrospective studies abroad to evaluate the efficacy and safety of trastuzumab and fulvestrant in the treatment of patients with HR+/HER2+ metastatic breast cancer
Combination therapy with trastuzumab and fulvestrant is a treatment option for patients with hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer; however, this combination therapy is currently being evaluated Efficacy studies are still limited
Data were retrospectively collected from patients with HR+/HER2+ metastatic breast cancer who received the combination of trastuzumab and fulvestrant between August 1997 and August 2020
.
The primary endpoint of this study was progression-free survival, and secondary endpoints were response rate, overall survival, and safety
Data were retrospectively collected from patients with HR+/HER2+ metastatic breast cancer who received the combination of trastuzumab and fulvestrant between August 1997 and August 2020
The study screened data from 1612 patients with recurrent or metastatic breast cancer, 118 of whom were diagnosed with HR+/HER2+ breast cancer
Complete remission (CR) was not observed in all patients
The median progression-free survival (PFS) was 6.
PFS and OS
PFS and OSPFS subgroup analysis
PFS subgroup analysisIn subgroup analysis, the median progression-free survival (PFS) was 7.
3 months (95% CI, 1.
53-18.
67) and the median OS was 7.
3 months (95% CI, 1.
53-18.
67) in patients treated with the combination of trastuzumab and fulvestrant as ≤3 lines of therapy Not reached
.
In contrast, patients treated as >3 lines had a median progression-free survival (PFS) of 5.
In subgroup analysis, the median progression-free survival (PFS) was 7.
Differences in PFS as different lines of treatment
Differences in PFS as different lines of treatmentIn addition, patients with liver metastases had a shorter median PFS than those without liver metastases, 3.
5 months (95% CI, 1.
17-8.
93) and 6.
9 months (95% CI, 3.
93-8.
17), respectively (log rank test, p = 0.
3573)
.
5 months (95% CI, 1.
17-8.
93) and 6.
9 months (95% CI, 3.
93-8.
17), respectively (log rank test, p = 0.
3573)
.
In addition, patients with liver metastases had a shorter median PFS than those without liver metastases, 3.
Differences in PFS with and without liver metastases
Differences in PFS with and without liver metastasesNo grade 3 adverse events were observed in the safety assessment
.
.
In conclusion, the study shows that the combination of trastuzumab and fulvestrant is safe and effective in the treatment of patients with HR+/HER2+ metastatic breast cancer, and can be used as an option after the progression of standard anti-HER2 therapy in this population
.
.
Studies have shown that the combination of trastuzumab and fulvestrant is safe and effective in patients with HR+/HER2+ metastatic breast cancer and can be used as an option after progression on standard anti-HER2 therapy in this population
.
Studies have shown that the combination of trastuzumab and fulvestrant is safe and effective in patients with HR+/HER2+ metastatic breast cancer and can be used as an option after progression on standard anti-HER2 therapy in this population
.
Original source:
Original source:Ozaki Y, Aoyama Y, Masuda J, Inagaki L, Kawai S, Shibayama T, Maeda T, Kurata M, Yoshida K, Saeki S, Hosonaga M, Fukada I, Hara F, Kobayashi T, Kobayashi K, Miyake S, Takano T , Ueno T, Ohno S.
Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.
BMC Cancer.
2022 Jan 4;22(1):36 .
doi: 10.
1186/s12885-021-09128-1.
PMID: 34983437; PMCID: PMC8728947.
Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.
BMC Cancer.
2022 Jan 4;22(1):36 .
doi: 10.
1186/s12885-021-09128-1.
PMID: 34983437; PMCID: PMC8728947.
Leave a message here
